Status:
COMPLETED
Effect of Vilanterol on Methacholine Challenge Results
Lead Sponsor:
University of Saskatchewan
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study will assess the degree of bronchoprotection provided by the ultra long-acting beta2 agonist vilanterol against methacholine-induced bronchoconstriction.
Detailed Description
This will be a double-blind, three-way crossover study comparing combination vilanterol+fluticasone with fluticasone monotherapy and a placebo (vilanterol is not available as a monotherapy). The order...
Eligibility Criteria
Inclusion
- men and women aged 18 or older
- stable mild-to-moderate asthma
- baseline methacholine PC20 less than or equal to 8mg/mL
- FEV1 greater than or equal to 65% of predicted
Exclusion
- Use of long-acting anticholinergic or long-acting beta2 agonist within 30 days of study
- pregnant or nursing
- diabetes
- hypokalemia
- cardiovascular, prostate, kidney, or urinary retention problems
- lactose-intolerant
- allergy-induced asthma symptoms or upper respiratory tract infection within four weeks of study
- current smokers
- past smokers with smoking history \>10 pack years
Key Trial Info
Start Date :
October 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03315000
Start Date
October 13 2017
End Date
May 1 2018
Last Update
October 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asthma Research Lab - University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8